Related Experiment Video
Updated: Jul 13, 2026
09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes
J E Holley1, J Newcombe, P G Winyard
1Institute of Biomedical and Clinical Science, Peninsula Medical School (Exeter), and Royal Devon and Exeter Hospital, Devon, UK. janet.holley@pms.ac.uk
Multiple Sclerosis (Houndmills, Basingstoke, England)
|July 12, 2007
Summary
Peroxiredoxin V (PRDX V) increases in multiple sclerosis (MS) brain lesions, particularly in astrocytes. This suggests ongoing oxidative stress in MS, even without active inflammation, highlighting potential therapeutic targets.
Area of Science:
- Neuroscience
- Immunology
- Biochemistry
Background:
- Oxidative stress contributes to multiple sclerosis (MS) pathogenesis.
- Antioxidants, like Peroxiredoxin V (PRDX V), combat oxidative damage.
- PRDX V's role in the human brain, especially in MS, is largely unknown.
Purpose of the Study:
- To investigate PRDX V expression in normal and MS human brain white matter.
- To determine PRDX V localization in different types of MS lesions.
- To explore the implications of PRDX V expression patterns in MS.
Main Methods:
- Immunohistochemistry and immunoblotting were used to analyze PRDX V expression.
- Human brain white matter samples from normal individuals (n=5) and MS patients (n=18) were studied.
- Tissue analysis included normal-appearing white matter (NAWM) and MS lesions (acute and chronic).
Main Results:
- PRDX V showed a global increase in MS NAWM compared to controls.
- The most significant PRDX V increase was observed in astrocytes within MS lesions.
- Strong PRDX V staining was found in reactive astrocytes in acute lesions and scar astrocytes in chronic lesions.
Conclusions:
- PRDX V expression is upregulated in the MS brain, especially in astrocytes within lesions.
- Elevated PRDX V in chronic MS lesions suggests persistent oxidative stress, independent of active inflammation.
- These findings indicate PRDX V as a potential biomarker and therapeutic target for MS.
